PharmaTimes reports that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Nuformix to commence its NXP001 human pharmacokinetics study. Nuformix is developing NXP001 as a treatment for chemotherapy-induced nausea and vomiting, a large, under-exploited and growing market. About one third of all cancer patients struggle with this issue. It represents a large market. This milestone triggers a payment of a final 2 million UK pound milestone by the firm’s China market partner and advancing product registration in China. It also supports Nuformix efforts to begin other commercialization outreach including partnerships and funding sources.
Who is Nuformix?
Founded in 2008, Nuformix has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities with an accompanying portfolio of intellectual property. Publicly traded, they trade as “NFX.” See their pipeline for more information.